Close X
Attorney Spotlight

What is Shannon Wiley looking forward to at this year's Asembia Specialty Pharmacy Summit? Find out more>


Close X


Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Download the Healthcare Fraud & Abuse Review 2017, authored by Bass, Berry & Sims

The Healthcare Fraud & Abuse Review 2017 details all healthcare-related False Claims Act settlements from last year, organized by particular sectors of the healthcare industry. In addition to reviewing all healthcare fraud-related settlements, the Review includes updates on enforcement-related litigation involving the Stark Law and Anti-Kickback Statute, and looks at the continued implications from the government's focus on enforcement efforts involving individual actors in connection with civil and criminal healthcare fraud investigations.

Click here to download the Review.

Janelle Waack Comments on Exclusivity Terms for Biologic Drugs in Trans-Pacific Partnership Agreement

Media Mentions

October 6, 2015

Bass, Berry & Sims attorney Janelle Waack provided comment for a Modern Healthcare article outlining the details of the Trans-Pacific Partnership Agreement, a trade agreement between the U.S. and 11 countries. As part of the agreement, countries will extend data exclusivity for biologic medicines for five to eight years instead of the 12 years that the United States and the pharmaceutical industry recommended. The trade agreement next goes to the U.S. Congress, who will need to vote whether to accept the deal. As Janelle points out in the article, Congress will need to "carefully consider the impact on the pharmaceutical industry and smaller companies that are doing the ground level research, saying the agreement raises questions about whether they would continue 'to pursue these lines of research in view of what could be a more limited period of exclusivity.'"

The full article, "Trade Deal Disappoints Drugmakers, Consumer Groups," was published by Modern Healthcare on October 5, 2015 and is available online.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.